Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May 24;61(6):e00258-17.
doi: 10.1128/AAC.00258-17. Print 2017 Jun.

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment

R M Anthony  1 , M Cynamon  2 , S Hoffner  3 , J Werngren  4 , A L den Hertog  5 , D van Soolingen  6
Affiliations
Comment

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment

R M Anthony et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: Mycobacterium tuberculosis; multidrug resistance; pyrazinamide.

PubMed Disclaimer

Comment in

Comment on

References

    1. Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. 2017. A multistrain mathematical model to investigate the role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 61:e00498-16. doi:10.1128/AAC.00498-16. - DOI - PMC - PubMed
    1. Wollenberg KR, Desjardins CA, Zalutskaya A, Slodovnikova V, Oler AJ, Quiñones Abeel T, Chapman SB, Tartakovsky M, Gabrielian A, Hoffner S, Skrahin A, Birren BW, Rosenthal A, Skrahina A, Earl AM. 2017. Whole-genome sequencing of Mycobacterium tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. J Clin Microbiol 55:457–469. doi:10.1128/JCM.02116-16. - DOI - PMC - PubMed
    1. Yee M, Gopal P, Dick T. 2017. Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 61:e02342-16. doi:10.1128/AAC.02342-16. - DOI - PMC - PubMed
    1. Zheng X, Zheng R, Hu Y, Werngren J, Forsman LD, Mansjö M, Xu B, Hoffner S. 2016. Determination of MIC breakpoints for second-line drugs associated with clinical outcomes in multidrug-resistant tuberculosis treatment in China. Antimicrob Agents Chemother 60:4786–4792. doi:10.1128/AAC.03008-15. - DOI - PMC - PubMed
    1. den Hertog AL, Sengstake S, Anthony RM. 2015. Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite? Pathog Dis 73:ftv037. doi:10.1093/femspd/ftv037. - DOI - PubMed

LinkOut - more resources